PVP-Guided Decongestive Therapy in HF 2

Primary end point: Major adverse events (Mortality and rehospitalization)

The difference in the combined rate of all-cause mortality, all-cause hospitalization and all-cause emergency department visits

Secondary combined end point:Major cardiac adverse events (Cardiac mortality and hospitalization)

The difference in the combined rate of cardiovascular mortality, HF-related hospitalization, HF-related emergency department visits.

PVP (discharge and delta) and long term outcomes

The correlation between predischarge the absolute amount of pre-discharge peripheral venous pressure (PVP in mmHg) and the change in PVP (in mmHg) during hospital stay and the rate of adverse long-term primary outcomes. (The higher the absolute PVP, more adverse outcomes is hypothesized. The higher the change in PVP during hospital stay, less the rate of adverse events is hypothesized). A multivariable analysis will also be executed for predicting the primary end point.

PVP (delta and cohort) and in-hospital renal outcomes

The correlation between the change in PVP during hospital stay (in mmHg) and the rate of worsening renal function, renal injury, need for dialysis or veno-venous ultrafiltration.

Congestion

The comparison of the two arms in terms of EVEREST congestion score (EVEREST congestion score, range 0-18, the higher the score, the higher the congestion (worse outcome))

Hospital stay

The comparison of the two arms in terms of hospital stay (in days). Longer hospital stay duration is deemed as worse outome.